-
1.发明申请公开(公告)号：US20140294837A1
公开(公告)日：2014-10-02
申请号：US14228521
申请日：2014-03-28
Applicant: SAMSUNG ELECTRONICS CO., LTD.
Inventor： Yun Jeong SONG , Ho Yeong SONG , Seung Hyun LEE , Kyung Ah KIM , Yun Ju JEONG
CPC classification number: C07K16/2863 , A61K2039/505 , C07K14/71 , C07K2317/10 , C07K2317/24 , C07K2317/515 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/00
Abstract: There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.
Abstract translation: 提供了通过偶联抗c-Met抗体和VEGF结合片段，包含融合蛋白的双特异性抗体，编码融合蛋白的多核苷酸，包含多核苷酸的转化体，包含双特异性抗体的药物组合物形成的融合蛋白 作为活性成分，以及同时制备靶向c-Met和VEGF的双特异性抗体的方法，具有改善的抗癌和抗血管生成作用，包括将抗c-Met抗体与VEGF结合偶联 分段。
-
公开(公告)号：US20130089542A1
公开(公告)日：2013-04-11
申请号：US13646589
申请日：2012-10-05
Applicant: Samsung Electronics Co. Ltd.
Inventor： Seung Hyun LEE , Kwang Ho CHEONG , Kyung Ah KIM , Ho Yeong SONG , Geun Woong KIM , Hye Won PARK , Young Mi OH , Saet Byoul LEE , Ji Min LEE , Yun Ju JEONG , Mi Young CHO , Jae Hyun CHOI , Yoon Aa CHOI
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
Abstract: An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.
Abstract translation: 抗c-Met抗体或抗体片段及包含其的药物组合物，以及通过向受试者施用抗体来预防和治疗癌症的方法。
-
Patent Agency Ranking
公开(公告)号：US20210269533A1
公开(公告)日：2021-09-02
申请号：US17193804
申请日：2021-03-05
Applicant: Samsung Electronics Co., Ltd.
Inventor： Seung Hyun LEE , Geun Woong KIM , Kyung Ah KIM , Hye Won PARK , Ho Yeong SONG , Young Mi OH , Saet Byoul LEE , Ji Min LEE , Kwang Ho CHEONG , Yun Ju JEONG , Mi Young CHO , Jae Hyun CHOI , Yun Jeong SONG , Yoon Aa CHOI
IPC: C07K16/28
Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.
-
4.发明申请USE OF LRIG1 AS A BIOMARKER FOR IDENTIFYING A SUBJECT FOR APPLICATION OF ANTI-C-MET ANTIBODIES 有权使用LRIG1作为生物标志物鉴定应用抗C-MET抗体的主体公开(公告)号：US20140105902A1
公开(公告)日：2014-04-17
申请号：US13949041
申请日：2013-07-23
Applicant: SAMSUNG ELECTRONICS CO., LTD.
Inventor： Ji Min LEE , Kyung Ah KIM , Bo Gyou KIM
IPC: G01N33/574 , C07K16/30 , C12Q1/68
CPC classification number: G01N33/57492 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57496 , G01N2800/52
Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.
Abstract translation: 一种鉴定适合用抗c-Met抗体或其抗原结合片段治疗的细胞样品或受试者的方法，所述抗c-Met抗体或其抗原结合片段特异性结合c-Met蛋白质的SEMA结构域中的表位，通过确定c-Met蛋白中存在LRIG1 来自受试者的细胞样品，以及相关方法和组合物。
-
5.发明申请USE OF CBL AS BIOMARKER FOR IDENTIFYING SUBJECT SUITABLE FOR TREATMENT WITH ANTI-C-MET ANTIBODY 有权使用CBL作为生物标志物鉴定适合用于抗C-MET抗体治疗的受试者公开(公告)号：US20140105901A1
公开(公告)日：2014-04-17
申请号：US13949012
申请日：2013-07-23
Applicant: SAMSUNG ELECTRONICS CO., LTD.
Inventor： Ji Min LEE , Kyung Ah KIM , Bo Gyou KIM , Young Mi OH , Saet Byoul LEE , Yun Ju JEONG
IPC: G01N33/574 , C07K16/30 , C12Q1/68
CPC classification number: G01N33/57492 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N2800/52 , A61K2300/00
Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.
Abstract translation: 一种鉴定细胞样本或适合于用抗c-Met抗体或其抗原结合片段治疗的受试者的方法，所述抗c-Met抗体或其抗原结合片段通过测定Cbl浓度特异性地结合c-Met蛋白质的SEMA结构域中的表位，Cbl 突变和/或与受试者的细胞样品中与Cbl相互作用的c-Met位点的突变，以及相关的组合物和方法。
-
公开(公告)号：US20160030559A1
公开(公告)日：2016-02-04
申请号：US14814278
申请日：2015-07-30
Applicant: Samsung Electronics Co., Ltd.
Inventor： Ji Min LEE , Bo Gyou KIM , Seung Ja OH , Kyung Ah KIM , Saet Byoul LEE , Jae Woong HWANG
IPC: A61K39/395 , G01N33/574 , A61K31/713 , C07K16/28 , A61K45/06
CPC classification number: A61K31/713 , A61K39/39533 , A61K39/39558 , A61K45/06 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/54 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , G01N33/57484 , G01N2800/52 , A61K2300/00 , A61K31/573
Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.
Abstract translation: 用于预测c-Met抑制剂，选择施用c-Met抑制剂的受试者或监测c-Met抑制剂的功效的生物标志物Hsp90以及使用Hsp90的相关方法。
-
7.发明申请METHOD OF COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES 有权用于预防或治疗C-MET或血管生成因子诱导性疾病的组合治疗方法公开(公告)号：US20140086926A1
公开(公告)日：2014-03-27
申请号：US14025403
申请日：2013-09-12
Applicant: Samsung Electronics Co., Ltd.
Inventor： Yun Ju JEONG , Kyung Ah KIM , Yun Jeong SONG , Ji Min LEE , Hyo Seon LEE , Jae Hyun CHOI , Saet Byoul LEE
IPC: A61K39/395 , A61K45/06
CPC classification number: A61K39/3955 , A61K45/06 , C07K16/2863 , C07K2317/24
Abstract: Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient.
Abstract translation: 提供了用于预防或治疗c-Met诱导或血管生成因子诱导的疾病的组合疗法的方法，包括向患者共同给予血管生成抑制剂和抗c-Met抗体或其抗原结合片段。
-
-
-
-
-
-
Search Results
7
records
(took 0.014 seconds)
